BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Condition: Relapsed And-or Refractory Multiple Myeloma and Plasmacytoid Lymphoma Intervention: Biological: BCMA-CD19 cCAR T cells Sponsors: iCell Gene Therapeutics; iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials